ALEXANDRIA, Va., April 9 -- United States Patent no. 12,269,880, issued on April 8, was assigned to Leidos Inc. (Reston, Va.).
"LAG3 binding peptides" was invented by Gabriel M. Gutierrez (Reston, Va.), Vinayaka Kotraiah (Reston, Va.), Timothy W. Phares (Reston, Va.), James Pannucci (Reston, Va.) and Marc Mansour (Reston, Va.).
According to the abstract* released by the U.S. Patent & Trademark Office: "This disclosure provides nucleic acids encoding peptides which bind to LAG3 and can be used to block the interaction of LAG 3 with other molecules such as MHC-II, FGL1, and Alpha-synuclein. These peptides can be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, or i...